ライフサイエンスコーパス: nonmelanoma skin cancer

1 most common cancer type among men (excluding nonmelanoma skin cancer).

2 they had a previous cancer diagnosis (except nonmelanoma skin cancer).

3 and 98 patients developed cancer (excluding nonmelanoma skin cancer).

4 mary cause of skin cancer (both melanoma and nonmelanoma skin cancer).

5 rt members, 730 reported 802 SMNs (excluding nonmelanoma skin cancers).

6 anding the pathogenesis of wound healing and nonmelanoma skin cancer.

7 aging nor a higher incidence for sun-induced nonmelanoma skin cancer.

8 se may offer a viable therapeutic option for nonmelanoma skin cancer.

9 nscreen use to prevent actinic keratoses and nonmelanoma skin cancer.

10 adiation in sunlight is the primary cause of nonmelanoma skin cancer.

11 t ranged from 48.7% for myeloma to 31.4% for nonmelanoma skin cancer.

12 llowing UV irradiation, the primary cause of nonmelanoma skin cancer.

13 the major risk factor for the development of nonmelanoma skin cancer.

14 c has been associated with increased risk of nonmelanoma skin cancer.

15 psoriasis patients are at increased risk for nonmelanoma skin cancer.

16 on plays a critical role in the induction of nonmelanoma skin cancer.

17 ng its potential as a therapeutic target for nonmelanoma skin cancer.

18 Mohs surgery for nonmelanoma skin cancer.

19 umor growth in solar-simulated light-induced nonmelanoma skin cancer.

20 a markedly reduced incidence of melanoma and nonmelanoma skin cancer.

21 outcome was total invasive cancer, excluding nonmelanoma skin cancer.

22 electrodesiccation and curettage in treating nonmelanoma skin cancer.

23 emal UVR and incident cancer risk, excluding nonmelanoma skin cancer.

24 global increase in incidence of melanoma and nonmelanoma skin cancer.

25 ith no previous history of cancer other than nonmelanoma skin cancer.

26 global increase in incidence of melanoma and nonmelanoma skin cancer.

27 sion, which contribute to the development of nonmelanoma skin cancer.

28 %]), attributable to the higher incidence of nonmelanoma skin cancer.

29 organ transplants have an increased risk for nonmelanoma skin cancer.

30 quitous in skin and has been associated with nonmelanoma skin cancer.

31 porine have an increased risk for developing nonmelanoma skin cancer.

32 ell carcinomas (MCCs), an aggressive form of nonmelanoma skin cancer.

33 human cancers, including melanoma and other nonmelanoma skin cancers.

34 ent of precancerous skin lesions and certain nonmelanoma skin cancers.

35 the most prevalent mutations found in human nonmelanoma skin cancers.

36 n phenotypes and development of melanoma and nonmelanoma skin cancers.

37 ic receptors as a new treatment modality for nonmelanoma skin cancers.

38 multiple tumor types, including melanoma and nonmelanoma skin cancers.

39 lignancies, 233 benign meningiomas, and 1856 nonmelanoma skin cancers.

40 or subsequent malignancies, meningiomas, and nonmelanoma skin cancers.

41 vents keratinocyte carcinomas, also known as nonmelanoma skin cancers.

42 a-HPVs) may contribute to the development of nonmelanoma skin cancers.

43 than heterosexual women to report having had nonmelanoma skin cancer (2001-2005 CHIS: aOR, 0.56; 95%

44 These included 196 SMNs, 419 nonmelanoma skin cancers, 21 nonmalignant meningiomas, a

45 most cancer sites, with large increases from nonmelanoma skin cancer (23.4, 21.5-25.5), NHL (5.17, 4.

46 ORRs were 69% (nonmelanoma skin cancer), 31% (NSCLC), 16% (HCC), and 11

47 Excluding nonmelanoma skin cancers, 55 second cancers were seen in

48 Importance: Keratinocyte carcinoma (nonmelanoma skin cancer) accounts for substantial burden

49 Incident cancer, excluding nonmelanoma skin cancer, after at least 90 days and with

50 and safety of specific treatments to prevent nonmelanoma skin cancers among solid organ transplant re

51 renal papillary, and rectal cancer and three nonmelanoma skin cancers) among 825 patients who receive

52 ctrum strikingly similar to that reported in nonmelanoma skin cancer and characteristic of DNA damage

53 l carcinoma (cSCC) is the second most common nonmelanoma skin cancer and commonly affects the head an

54 Diagnosis of melanoma or nonmelanoma skin cancer and frequent excisions for benig

55 present in sunlight is the primary cause of nonmelanoma skin cancer and has been implicated in the d

56 pants received a cancer diagnosis, excluding nonmelanoma skin cancer and in situ neoplasms.

57 Nonmelanoma skin cancer and its treatment represent a si

58 ntial and increasing risk for SNs, including nonmelanoma skin cancer and meningiomas.

59 Increases in nonmelanoma skin cancer and nonprogressive, reversible r

60 aviolet A dramatically increases the risk of nonmelanoma skin cancer and prior exposure to psoralen+u

61 reast cancer is the most common cancer after nonmelanoma skin cancer and the second leading cause of

62 vation was clear for all main cancers except nonmelanoma skin cancer and was stronger for cancers of

63 e and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-r

64 Two nonmelanoma skin cancers and two major adverse cardiovas

65 of breast cancer or other cancers (excluding nonmelanoma skin cancer), and we completed a personal ba

66 nt, severity of AK (Olsen grade), history of nonmelanoma skin cancer, and additional treatment.

67 r TMB and older age at diagnosis, history of nonmelanoma skin cancer, and head and neck tumors relati

68 -degree family history of melanoma, previous nonmelanoma skin cancer, and lifetime sunbed use.

69 feature of diseases like psoriasis, eczema, nonmelanoma skin cancer, and melanoma where differentiat

70 ve an increased incidence of viral warts and nonmelanoma skin cancer, and the presence of HPV DNA in

71 rs, six non-MDS hematologic malignancies, 39 nonmelanoma skin cancers, and 68 cases of MDS/acute myel

72 An estimated 5.4 million cases of nonmelanoma skin cancer are reported in the United State

73 Nonmelanoma skin cancers are among the most common human

74 More than a million cases of nonmelanoma skin cancers are diagnosed every year.

75 ecent dramatic increases in the incidence of nonmelanoma skin cancers are largely attributable to hig

76 Nonmelanoma skin cancers are primarily caused by solar U

77 1273 men had any malignant neoplasm (except nonmelanoma skin cancer), as compared with 1293 in the p

78 low-up, previous cancer diagnosis (excluding nonmelanoma skin cancer) at enrollment, missing enrollme

79 ohort who had no cancer diagnosis (excluding nonmelanoma skin cancer) at the start of follow-up and r

80 ts an avoidable risk factor for melanoma and nonmelanoma skin cancer - both of which may be lethal.

81 bronchus, and lung; malignant skin melanoma; nonmelanoma skin cancer; breast; cervical; uterine; ovar

82 UVR is the major cause of nonmelanoma skin cancer, but other risk factors, includi

83 Administration approved for the treatment of nonmelanoma skin cancers, but it has limited activity ag

84 s that beta-HPV infections may contribute to nonmelanoma skin cancer by increasing the likelihood tha

85 UV radiation may lead to melanoma and nonmelanoma skin cancers by causing helix-distorting DNA

86 Prespecified outcomes were nonmelanoma skin cancer, clearance and prevention of ker

87 It is clear that melanoma and nonmelanoma skin cancer control programs combining prima

88 ity of Pennsylvania, who were diagnosed with nonmelanoma skin cancer, dermatophytosis, acne rosacea,

89 a causative role in ODC up-regulation during nonmelanoma skin cancer development by binding to and st

90 5 cells) to explore the regulation of ODC in nonmelanoma skin cancer development.

91 There were two reported cases of nonmelanoma skin cancer during the follow up of the tran

92 eningiomas, and 1.71 (95% CI, 0.88-3.33) for nonmelanoma skin cancers for survivors with reference ch

93 the detection of positive section margins in nonmelanoma skin cancer from 8.4% to 12.8%.

94 the detection of positive section margins in nonmelanoma skin cancer from 8.4% to 12.8%.

95 Combined cancer incidence (excluding nonmelanoma skin cancers) from 1987 to 2006 was captured

96 ng, had no prior cancer diagnosis other than nonmelanoma skin cancer, had no prior cancer genetic cou

97 The incidence of both melanoma and nonmelanoma skin cancer has been increasing over the pas

98 ll effect of screening for both melanoma and nonmelanoma skin cancers has not been achieved.

99 AIH was also linked to nonmelanoma skin cancer (hazard ratio (HR) = 2.69) and l

100 y, we recruited 647 patients with carcinoma, nonmelanoma skin cancer, hematological second cancer, an

101 The primary end point was the number of new nonmelanoma skin cancers (i.e., basal-cell carcinomas pl

102 riant was also significantly associated with nonmelanoma skin cancer in a U.K. population.

103 ated with a dose-dependent increased risk of nonmelanoma skin cancer in patients treated for psoriasi

104 play an important part in the development of nonmelanoma skin cancer in psoralen + ultraviolet A-trea

105 nefits and harms of interventions to prevent nonmelanoma skin cancer in solid organ transplant recipi

106 age/repair and prevention of photodamage and nonmelanoma skin cancer in vitiligo.

107 12-month intervention period, the number of nonmelanoma skin cancers in the 6-month postintervention

108 o, 386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years to rece

109 Nonmelanoma skin cancers, in particular cutaneous squamo

110 same cumulative dose, which may explain why nonmelanoma skin cancer incidence depends more strongly

111 e finding of TRPV4 downregulation in several nonmelanoma skin cancers into context.

112 Nonmelanoma skin cancer is the most common cancer in the

113 While a high risk of nonmelanoma skin cancer is well recognized in solid-orga

114 Nonmelanoma skin cancer, Kaposi sarcoma, and posttranspl

115 The elevated risks of nonmelanoma skin cancers might indicate an association w

116 rved being central nervous system (n = 344), nonmelanoma skin cancer (n = 278), digestive (n = 105),

117 mon type of previous cancer in the donor was nonmelanoma skin cancer (n=776) followed by central nerv

118 Excluding nonmelanoma skin cancers (n = 19) and carcinoma-in-situ

119 le of mitochondrial DNA (mtDNA) deletions in nonmelanoma skin cancer (NMSC) and in cutaneous photoagi

120 erum 25-hydroxyvitamin D levels with risk of nonmelanoma skin cancer (NMSC) and melanoma, we evaluate

121 the United States, Europe, and Australia for nonmelanoma skin cancer (NMSC) and melanoma.

122 Protective effects of UV-B radiation against nonmelanoma skin cancer (NMSC) are exerted via signaling

123 ndependently reviewed the DSCMs for residual nonmelanoma skin cancer (NMSC) before and after a brief

124 are suspected to promote the development of nonmelanoma skin cancer (NMSC) by destabilizing the host

125 on-exposed survivors who developed an SN1 of nonmelanoma skin cancer (NMSC) had a cumulative incidenc

126 Nonmelanoma skin cancer (NMSC) has become the most commo

127 accurate measurement of the US incidence of nonmelanoma skin cancer (NMSC) has been difficult.

128 aimed to determine the risk of melanoma and nonmelanoma skin cancer (NMSC) in patients with IBD and

129 was to assess trends in mortality rates for nonmelanoma skin cancer (NMSC) in the United States.

130 osure or other factors, and the incidence of nonmelanoma skin cancer (NMSC) is poorly understood.

131 Nonmelanoma skin cancer (NMSC) is the most common cancer

132 Nonmelanoma skin cancer (NMSC) occurs in photoexposed ar

133 Patients with a periocular region nonmelanoma skin cancer (NMSC) or a nonperiocular NMSC c

134 ot have a greater than expected incidence of nonmelanoma skin cancer (NMSC) or other cancers, whereas

135 Nonmelanoma skin cancer (NMSC) such as cutaneous squamou

136 th 95% CIs for any incident cancer excluding nonmelanoma skin cancer (NMSC) were 1.06 (95% CI, 1.02-1

137 e highly effective in preventing UVB-induced nonmelanoma skin cancer (NMSC) without displaying any ov

138 nd squamous cell carcinoma (typically called nonmelanoma skin cancer (NMSC)).

139 e intake and risks of skin cancer (overall), nonmelanoma skin cancer (NMSC), and basal cell carcinoma

140 d higher risk than HIV-uninfected persons of nonmelanoma skin cancer (NMSC), defined as basal cell ca

141 Various treatment options exist for nonmelanoma skin cancer (NMSC), including topical agents

142 During Mohs micrographic surgery of nonmelanoma skin cancer (NMSC), inflammation in histolog

143 duced immunosuppression is a risk factor for nonmelanoma skin cancer (NMSC), particularly squamous ce

144 ng Medicare billing codes and categorized as nonmelanoma skin cancer (NMSC), viral-linked and "other"

145 in a single patient were counted, except for nonmelanoma skin cancer (NMSC), where only the first was

146 player in the development and progression of nonmelanoma skin cancer (NMSC).

147 a and certain noncutaneous cancers following nonmelanoma skin cancer (NMSC).

148 ging is associated with an increased risk of nonmelanoma skin cancer (NMSC).

149 dergoing Mohs micrographic surgery (MMS) for nonmelanoma skin cancer (NMSC).

150 een used as sampling frames for ascertaining nonmelanoma skin cancer (NMSC).

151 cies (malignancies), including and excluding nonmelanoma skin cancer (NMSC); all malignancies were ex

152 in a case-control study of 191 patients with nonmelanoma skin cancer (NMSC; 81 SCC and 110 basal cell

153 Nonmelanoma skin cancers (NMSC) are among the most commo

154 V) have been suspected to be carcinogenic in nonmelanoma skin cancers (NMSC), but the basis for poten

155 Cancer registries usually exclude nonmelanoma skin cancers (NMSC), despite the large popul

156 Nonmelanoma skin cancers (NMSCs) are primarily diagnosed

157 Nonmelanoma skin cancers (NMSCs) are the most common can

158 Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated

159 ous basal cell and squamous cell carcinomas (nonmelanoma skin cancers (NMSCs)), data are insufficient

160 ght to be involved in the initiation of some nonmelanoma skin cancers (NMSCs), particularly in patien

161 des further evidence that for primary facial nonmelanoma skin cancers (NMSCs), recurrence rates with

162 neoplasms, increases the risk of developing nonmelanoma skin cancers (NMSCs).

163 with briakinumab vs. placebo, respectively), nonmelanoma skin cancers (NMSCs; four vs. zero squamous

164 ent SMNs were thyroid cancer, breast cancer, nonmelanoma skin cancer, non-Hodgkin's lymphoma, and acu

165 Nonmelanoma skin cancers occur primarily in individuals

166 Across all three trials, adjudicated nonmelanoma skin cancer occurred in five patients who re

167 squamous cell carcinoma (SCC) (often termed nonmelanoma skin cancer or keratinocyte carcinoma [KC])

168 21; 95% CI, 1.51-6.58; P < .003), and having nonmelanoma skin cancer (OR, 8.32; 95% CI, 2.81-21.13; P

169 et A is associated with an increased risk of nonmelanoma skin cancer, particularly squamous cell carc

170 aft-versus-host disease as a risk factor for nonmelanoma skin cancer, particularly squamous cell carc

171 lomaviruses (HPVs) have been associated with nonmelanoma skin cancers, particularly in immunocompromi

172 hree patients who underwent Mohs surgery for nonmelanoma skin cancers presented between 2 and 4 weeks

173 an papilloma virus infections and associated nonmelanoma skin cancers, providing additional genetic a

174 a US population-based case-control study of nonmelanoma skin cancer, randomly selected from drivers'

175 that can reduce mortality from melanoma and nonmelanoma skin cancer, screening holds the greatest pr

176 found moderately increased SIR estimates for nonmelanoma skin cancer, smoking-related cancers, and Ho

177 Incidence of melanoma, nonmelanoma skin cancers (squamous cell carcinoma and ba

178 Nonmelanoma skin cancer such as cutaneous squamous cell

179 Nonmelanoma skin cancers, such as basal-cell carcinoma a

180 Nonmelanoma skin cancers that required at least 3 Mohs m

181 e exposure to sunlight increases the risk of nonmelanoma skin cancer, the avoidance of all direct sun

182 iolet (UV) irradiation is the major cause of nonmelanoma skin cancer, the most common form of cancer

183 identified Zmiz1 as a candidate oncogene in nonmelanoma skin cancer through a transposon mutagenesis

184 ium SCT) is a novel noninvasive radionuclide nonmelanoma skin cancer treatment, which can be provided

185 sented ideas can easily be extended to other nonmelanoma skin cancer trials.

186 ), squamous cell carcinoma of the skin (CD), nonmelanoma skin cancer (UC), kidney (CD), and thyroid c

187 were adjusted based on age, sex, history of nonmelanoma skin cancer, US geographic region, and popul

188 tocols and disability, dermatitis, melanoma, nonmelanoma skin cancer, viral skin diseases, and fungal

189 ative incidence of SMNs was 9.3% and that of nonmelanoma skin cancer was 6.9%.

190 A trend toward decreased risk of nonmelanoma skin cancer was found in those harboring a g

191 the 10 most common cancers in the US and of nonmelanoma skin cancer was not increased with TNFalpha

192 Nonmelanoma skin cancer was not observed among irradiate

193 An excess risk of nonmelanoma skin cancer was observed subsequent to both

194 At 12 months, the rate of new nonmelanoma skin cancers was lower by 23% (95% confidenc

195 role of the Fragile Histidine Triad gene in nonmelanoma skin cancer, we have used reverse transcript

196 n, 66 cases of meningioma and 1,007 cases of nonmelanoma skin cancer were diagnosed.

197 with a personal history of cancer other than nonmelanoma skin cancer were excluded.

198 Effects on nonmelanoma skin cancer were uncertain for photodynamic

199 .44-4.27) with placebo/dexamethasone; IRs of nonmelanoma skin cancers were 2.40 (95% CI, 1.33-4.33) a

200 SMNs), and relative risks (RRs) for SMNs and nonmelanoma skin cancers were calculated.

201 Second primary malignancies excluding nonmelanoma skin cancers were seen in 5.5% and myeloid m

202 d who had no prior history of cancer (except nonmelanoma skin cancer) were followed prospectively for

203 ccurring > 5 years from diagnosis, excluding nonmelanoma skin cancers, were evaluated in survivors di

204 the incidence of all-type cancer (excluding nonmelanoma skin cancers), which was evaluated using Kap

205 a (MCC) is a highly malignant neuroendocrine nonmelanoma skin cancer, which is associated with the Me

206 IN OUTCOME MEASURES: Total cancer (excluding nonmelanoma skin cancer), with prostate, colorectal, and